The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
Abstract
How dying tumor cells get noticed: Besides killing tumor cells directly, some chemotherapies, such as anthracyclines, also activate the immune system to kill tumors. Vacchelli et al. discovered that in mice, anthracycline-induced antitumor immunity requires immune cells to express the protein formyl peptide receptor 1 (FPR1). Dendritic cells (DCs) near tumors expressed especially high amounts of FPR1. DCs normally capture fragments of dying tumor cells and use them to activate nearby T cells to kill tumors, but DCs lacking FPR1 failed to do this effectively. Individuals with breast or colon cancer expressing a variant of FPR1 and treated with anthracyclines showed poor metastasis-free and overall survival. Thus, FPR1 may affect anti-tumor immunity in people, too. Science , this issue p. 972
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This confirmed that Fpr1 deficient immune cells interacted much less with dying cancer cells treated with anthracyclines than immune cells expressing functional Fpr1 (Fig. 3B), explaining why Fpr1 deficiency leads to defective anticancer immune response and less efficient chemotherapy.”
From Microfluidics: A New Tool for Modeling Cancer–Immune Interactions (2016) · cites this paper as [62]
In the citing paper
“Recently, Vacchelli et al. identified a loss of-function mutation in the allele of the gene coding for formyl peptide receptor 1 (Fpr1) that correlated with poor survival in breast and colorectal cancer patients receiving adjuvant chemotherapy[62].”
From Microfluidics: A New Tool for Modeling Cancer–Immune Interactions (2016) · cites this paper as [62]
In the citing paper
“Extracellular ANXA1 reportedly acts as a DAMP and supports the activation of adaptive immune responses by engaging formyl peptide receptor 1 (FPR1) on DCs [876].”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [876]
In the citing paper
“In line with these observations, RCD is not perceived as immunogenic when cancer cells are depleted of HMGB1 or ANXA1, as well as when the host lacks TLR4 or FPR1 [870, 876].”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [876]
Citations
Cites
Fiji: an open-source platform for biological-image analysis
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2019 · Cited by 66,890
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Maere, S., Heymans, K., & Kuiper, M. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti551 · Cited by 4,155
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Self-citationApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Self-citationMore powerful procedures for multiple significance testing
Hochberg, Y., & Benjamini, Y. (1990) · Statistics in Medicine · doi:10.1002/sim.4780090710 · Cited by 2,715
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Self-citationDenkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., Budczies, J., Darb-Esfahani, S., Kronenwett, R., Hanusch, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7370 · Cited by 1,762
Cited by
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Self-citationTumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Self-citationDendritic cells in cancer immunology and immunotherapy
Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0210-z · Cited by 2,574
Metadata
- Authors
- Vacchelli, E., Ma, Y., Baracco, E. E., Sistigu, A., Enot, D. P., Pietrocola, F., Yang, H., Adjemian, S., Chaba, K., Semeraro, M., Signore, M., De Ninno, A., Lucarini, V., Peschiaroli, F., Businaro, L., Gerardino, A., Manic, G., Ulas, T., Günther, P., Schultze, J. L., Kepp, O., Stoll, G., Lefebvre, C., Mulot, C., Castoldi, F., Rusakiewicz, S., Ladoire, S., Apetoh, L., Bravo-San Pedro, J. M., Lucattelli, M., Delarasse, C., Boige, V., Ducreux, M., Delaloge, S., Borg, C., André, F., Schiavoni, G., Vitale, I., Laurent-Puig, P., Mattei, F., Zitvogel, L., & Kroemer, G.
- Affiliations
- Inserm (FR)
- Instituto Nazionale Tumori Regina Elena (IT)
- Gustave Roussy Cancer Campus, Villejuif, France.
- Istituto Superiore di Sanità (IT)
- Italian National Research Council, Institute for Photonics and Nanotechnology, Rome, Italy.
- National Research Council (IT)
- University of Bonn (DE)
- Centre Georges François Leclerc (FR)
- Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.
- University of Siena (IT)
- Centre National de la Recherche Scientifique (FR)
- Université Paris-Saclay (FR)
- University of Rome Tor Vergata (IT)
- Université Paris Sorbonne Cité, UMRS 775, INSERM, Paris, France.
- Karolinska University Hospital (SE)
- Corresponding author
- Zitvogel, Laurence
- ORCID
- Vacchelli, Erika
- Ma, Yuting
- Sistigu, Antonella
- Pietrocola, Federico
- Yang, Heng
- Adjemian, Sandy
- Signore, Michele
- Businaro, Luca
- Gerardino, Annamaria
- Manic, Gwenola
- Ulas, Thomas
- Günther, Patrick
- Schultze, Joachim L.
- Kepp, Oliver
- Stoll, Gautier
- Mulot, Claire
- Castoldi, Francesca
- Rusakiewicz, Sylvie
- Ladoire, Sylvain
- Lucattelli, Monica
- Delarasse, Cécile
- Boige, Valérie
- Ducreux, Michel
- Delaloge, Suzette
- Borg, Christophe
- André, Fabrice
- Schiavoni, Giovanna
- Vitale, Ilio
- Mattei, Fabrizio
- Zitvogel, Laurence
- Kroemer, Guido
- Venue
- Science
- Published
- 2015-11-20
- Volume
- 350
- Issue
- 6263
- Pages
- 972-978
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1911271782
- Cited by
- 452
- References
- 40
- Citations by year
- 2026: 25 · 2025: 25 · 2024: 29 · 2023: 51 · 2022: 38 · 2021: 50 · 2020: 58 · 2019: 47 · 2018: 45 · 2017: 40 · 2016: 42 · 2015: 1
- FWCI
- 20.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-10-LABX-0015, ANR-10-INBS-0001, ANR-10-IBHU-0001)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- FPR1, anthracycline chemotherapy, antitumor immunity, annexin A1, cancer cell death, T cell immunity, breast cancer, colorectal cancer, adjuvant chemotherapy, loss-of-function alleles, microfluidics, metastasis-free survival
- MeSH terms
- Alleles, Animals, Breast Neoplasms, Dendritic Cells, Female, Humans, Immunity, Innate, Leukocytes, Neoplasms, T-Lymphocytes, Colorectal Neoplasms, Chemotherapy, Adjuvant, Annexin A1, Anthracyclines, Polymorphism, Single Nucleotide, Receptors, Formyl Peptide, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. https://app.cochat.ai/papers/10.1126/science.aad0779
- The paper
- Vacchelli, E., Ma, Y., Baracco, E. E., Sistigu, A., Enot, D. P., Pietrocola, F., Yang, H., Adjemian, S., Chaba, K., Semeraro, M., Signore, M., De Ninno, A., Lucarini, V., Peschiaroli, F., Businaro, L., Gerardino, A., Manic, G., Ulas, T., Günther, P., . . . Kroemer, G. (2015). Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science. https://doi.org/10.1126/science.aad0779
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.